Restaurant CEOs seem pretty confident that sales will hold up just fine as the use of GLP-1 drugs increases, Daniela Sirtori-Cortina, Bloomberg News restaurant reporter, tells BI. In this episode of the Choppin’ It Up podcast, Sirtori-Cortina sits down with BI’s senior restaurant and foodservice analyst Michael Halen to discuss how drugs like Ozempic are forcing chains to consider salads, chicken and smaller portions. She also comments on the popularity of small indulgences amid a consumer slowdown and productivity improvements at Starbucks and Popeyes.